Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database

ObjectiveTreatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Patrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Astrid Schmieder, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Patrick Wurth, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Johannes Heck, Martin Welcker, Stefan Kleinert
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Frontiers Media S.A. 2024-05-01
Serie:	Frontiers in Immunology
Ämnen:	treatment persistence tofacitinib upadacitinib ustekinumab real-world biologics
Länkar:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1395968/full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!